{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the confidence interval was not estimable due to insufficient number of events","groupId":"OG000","lowerLimit":"27.9","upperLimit":"NA","value":"169"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"Treatment-free survival defined as the time from the date of start of TFR to the date of earliest occurrence of any of the following events: loss of MMR, confirmed loss of MR4, re-initiation of nilotinib treatment due to any cause, progression to acute phase (AP) or blast crisis (BC) or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","id":"OG000","title":"TFS Phase"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) included all patients who completed the consolidation phase successfully and entered the TFR phase.","reportingStatus":"POSTED","timeFrame":"nilotinib cessation up to approximately 580 weeks","title":"Treatment Free Survival (TFS) After the Start of the TFR Phase","type":"SECONDARY","unitOfMeasure":"Weeks"}